Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q2 2022 · 10-Q
Revenue$39.66M$39.66M+4.0% vs Q2 2021 Net Income-$2.84M-$2.84MN/M vs Q2 2021 EPS Diluted-$0.20-$0.20N/M vs Q2 2021 Gross Profit$24,862,000+19.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
Operating Cash Flowderived$3,088,000−28.1% Free Cash Flowderived$1,148,000−42.0% Margins · derivedGross margin62.7%+8.1 pt vs Q2 2021
Operating margin-8.5%−32.6 pt vs Q2 2021
Net margin-7.2%−24.3 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 4, 2022 · 35 d after period end